Osi thanks for post.
"I've been trying to search out where Celera may be up to with their blood test kit for lung cancer."
??-worthy endavour. I doubt any of it will transpire for ages. I think of it as typical ?
?? ?Biotec incubation line. It is well factored in by market, ie owl's report?
"The commercialised version of the test will either use 9 or 6 protein markers. While there is no guarantee that the MK linked protien will be in the final cut, it will be one of the 9. My speculative guess is that it is one of the 6, otherwise, why would they purchase a license from CDY?"
?? -There is no doubt in my mind that Midkine is a VERY important marker. It is thus on acccount of its cumulative presence in cancer. At this stage my construct is that MK functions as the supply channel of food for cancer. It is an insulin binded bridge. I visualise an integrated signalling cupboard, with direct access to cancer sites ordering, delivering what ever food will sustain cancer progression.?
?? ? ?SO the bigger the cancer the higher the Midkine presence both in plasma and on cancer zones. THEREFORE i understand that a base marking for Midkine presence is essential to prognosis. If Midkine levels drops in course of therapy, prognosis is good. If Midkine level is high when cancer is first diagnosed with other means, prognosis is poor.
?It is early days for Midkine. The Japanes team has reviewed the most virulant cancers, correlated Midkine reading in their different forms, in different cancer tissues, with plasma Midkine levels. They conclude that Midkine functions as a cancer marker and prognosis marker. The article is published on 20 april 2010.?
Midkine presents in many forms in both blood and cancer tissues. Base levels are being established for many populations, cancer types, age groups...eg, the Midkine conference in Sydney which workshoped and study Midkine already.
We can look forward to more Celera like deals arising from the Sydney conference.
Multiples of Celera deals are in the pipes.
Midkine is not merely a vague inflamation marker. It functions as a first port of call in diagnosis and a desease evolution marker.
I club it together. ?Do your own research
- Forums
- ASX - By Stock
- AN1
- broad applications discovery
AN1
anagenics limited
Add to My Watchlist
0.00%
!
0.6¢

broad applications discovery, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.977M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $1.885K | 272.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 680000 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 1103713 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 680000 | 0.006 |
2 | 600000 | 0.005 |
7 | 8064999 | 0.004 |
5 | 6358888 | 0.003 |
2 | 2800000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 1103713 | 3 |
0.009 | 520000 | 1 |
0.010 | 500000 | 1 |
0.015 | 200000 | 1 |
0.016 | 93390 | 1 |
Last trade - 15.53pm 11/07/2025 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
The Watchlist
VMM
VIRIDIS MINING AND MINERALS LIMITED
Rafael Moreno, CEO
Rafael Moreno
CEO
SPONSORED BY The Market Online